Cancer treatment acquisition should improve Nuvilex's valuation Print E-mail
By Staff and Wire Reports   
Wednesday, 01 June 2011 12:07

NuvilexShares of Nuvilex (OTCQB:NVLX) continue to trade higher after the company announced favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer.

The market has reacted favorably to the news because pancreatic cancer is often advanced when it is first found and very few pancreatic tumors can be removed by surgery. Once the tumor has spread (metastasized) to other organs such as the liver, chemotherapy alone is usually used but can only help approximately 25% of patients.

According to our sources, the treatment technology used in this trial was recently acquired by Nuvilex from a private European firm and is part of the company’s recently announced aggressive biotechnology growth agenda.

The firm recently revamped their previous management with Dr. Robert F. Ryan, whose expertise in cellular microbiolgy has re-energized the firm with plans to execute several licensing agreements and acquisitions of even more specific targeted technologies aimed to boost company credibility as an emerging player in biotech. Speculators have begun moving into the stock betting that Ryan’s actions will increase the firm’s valuation by immediately boosting Nuvilex’s pipeline and placing the firm’s new treatment candidate immediately into the U.S. regulatory pathway with an FDA sanctioned late-stage clinical trial- most likely a Phase IIB or Phase III trial.

According to statements released by the company, the European trial of the newly acquired technology demonstrated both efficacy and an improvement in quality of life, due in large part to the reduction in toxicity levels from lower dose chemotherapy. The treatment, which involved placing encapsulated cells into the pancreatic tumor and comparing efficacy against Gemzar®- the current gold standard chemotherapy, saw significant benefits including:

•    Results demonstrated a 100% increase in patients’ median survival rate
•    The 1-year survival rate was twice that observed with the current gold standard
•    Chemotherapy dose needed was only one-third the normal amount
•    Improved quality of life was noted in more than half of the patients

None of the fourteen patients treated with the new technology showed disease progression over the course of the trial and obvious tumor shrinkage was documented. The average pancreatic cancer patient survival was extended to 40 weeks compared to only 24 weeks using the current gold standard treatment. Nuvilex officials indicated that there are more positive developments in the works and set to be announced shortly.

There appears to be a considerable short position in the stock which may force some covering and buy-ins if the news flow from the company continues to be positive in the short term. Until recently, shares of the company appeared to be headed nowhere and were trading at only $.02. BioMedReports' premium subscribers were alerted to the shares when the stock was trading at $.06 less than 48 hours ago.

The chart shows some positive momentum and increasing volume levels with more room to run. Our advice to subscribers has been to set stops and continue to ride the momentum higher- particularly if shares break through the $.10 mark, where that short squeeze will be triggered.

Disclosure: None

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus